Canaccord raised the firm’s price target on BioNTech to $171 from $168 and keeps a Buy rating on the shares. The firm believes the company’s oncology pipeline has some late stage programs which they expect to be thesis- changing year or two. They see multiple blockbusters, and a nice combination of next-gen versions of validated approaches, as well as novel, potentially game-changing and broadly applicable approaches.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNTX:
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
- BioNTech, Autolus Therapeutics announce strategic alliance
- Lost Money in MBLY, BNTX, DADA, INSP or ON? Class Action Suits Filed, Seeking Recovery
- BioNTech and Duality announce FDA Fast track designation for BNT325/DB-1305
- BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
